Use and indication of vitamin D and vitamin D analogues in patients with renal bone disease

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 10, 2002, Pages 6-9

  Malluche, Hartmut H ^a   Monier Faugere, Marie Claude ^a   Koszewski, Nick J ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Bone turnover; Calcitriol; OCT; Parathyroid hormone; Renal failure; Vitamin D analogues

Indexed keywords

22 OXACALCITRIOL; CALCITRIOL; DNA; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PLACEBO; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BONE BIOPSY; BONE METABOLISM; BONE TURNOVER; CALCIFICATION; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA BINDING; DOSE RESPONSE; DRUG INDICATION; DRUG PULSE THERAPY; DRUG USE; HORMONE ACTION; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY FAILURE; MORBIDITY; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PATHOGENESIS; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; RISK FACTOR; VITAMIN BLOOD LEVEL;

EID: 0036413439     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_10.6     Document Type: Article

References (18)

1. Haussler MR, Whitfield GK, Haussler CA et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998; 13: 325-349
2. Rachez C, Freedman LP. Mechanisms of gene regulation by vitamin D(3) receptor: a network of coactivator interactions. Gene 2000; 246: 9-21
3. Sandgren ME, Bronnegard M, DeLuca HF. Tissue distribution of the 1,25-dihydroxyvitamin D3 receptor in the male rat. Biochem Biophys Res Commun 1991; 181: 611-616
4. Stumpf WE. Vitamin D sites and mechanisms of action: a histochemical perspective. Reflections on the utility of autoradiography and cytopharmacology for drug targeting. Histochem Cell Biol 1995; 104: 417-427
5. Malluche H, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990; 38: 193-211
6. Malluche H, Monier-Faugere M. Hyperphosphatemia: pharmacologic intervention. Yesterday, today, and tomorrow. Clin Nephrol 2000; 54: 309-317
7. Sawaya BP, Koszewski NJ, Qi Q et al. Secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements in rats with incipient renal failure. J Am Soc Nephrol 1997; 8: 271-278
8. Lucas P, Brown R, Jones C et al. Reduced 1,25(OH)2D3 may be responsible for the development of hyperparathyroidism in early chronic renal failure. Proc EDTA 1985; 22: 1124-1128
9. Baker LR, Abrams L, Roe CJ et al. 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 1989; 35: 661-669
10. Malluche HH, Matthews C, Faugere MC et al. 1,25-Dihydroxyvitamin D maintains bone cell activity, and parathyroid hormone modulates bone cell number in dogs. Endocrinology 1986; 119: 1298-1304
11. Monier-Faugere MC, Geng Z, Mawad H et al. Improved assessment of bone turnover by the PTH(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60: 1460-1468
12. Kurz P, Monier-Faugere MC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861
13. Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 1992; 38: S62-S67
14. Malluche HH, Monier-Faugere MC. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 1994; 4: 1631-1642
15. Brossard JH, Cloutier M, Roy L et al. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996; 81:3923-3929
16. Slatopolsky E, Finch J, Clay P et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58:753-761
17. Faugere MC, Langub MC, Malluche HH. The effects of PTH(1-84) on bone turnover are antagonized by PTH(7-84) in thyroparathyroidectomized and nephrectomized rats (abstract). J Am Soc Nephrol 2001; 12: 764A
18. Monier-Faugere MC, Geng Z, Friedler RM et al. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 1999; 55: 821-832